Credit: Avita Medical. The RECELL System is a single-use, autologous cell harvesting device. The Food and Drug Administration (FDA) has approved the RECELL ® System for the treatment of vitiligo. The ...
VALENCIA, Calif. and MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (RCEL) (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and ...
In its second approval this month from the U.S. FDA, Avita Medical Inc.’s Recell system received premarket approval for the repigmentation of stable depigmented vitiligo lesions. The approval marks ...
Investigator-initiated randomized controlled combination trial published in the International Journal of Dermatology confirms its superiority to monotherapy, fueling continued market growth and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback